p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart

Circulation

Volumn 111, Issue 19, 2005, Pages 2494-2502

  Li, Manxiang ^a   Georgakopoulos, Dimitrios ^b   Lu, Gang ^c   Hester, Lisa ^a   Kass, David A ^b   Hasday, Jeffery ^a   Wang, Yibin ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiomyopathy; Heart failure; Inflammation; Signal transduction

Indexed keywords

GELATINASE A; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SB 239068; TAPI 0; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GENE CONTROL; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; CYTOKINES; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18844461232     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000165117.71483.0C     Document Type: Article

References (62)

1. 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2002.
2. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling: behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569-582.
3. Spinale FG, Coker ML, Bond BR, Zellner JL, Mann DL. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
4. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000;35:537-544.
5. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol. 2003;65:81-101.
6. Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J. 2004;45:183-193.
7. Kapadia S, Dibbs Z, Kurrelmeyer K, Kalra D, Seta Y, Wang F, Bozkurt B, Oral H, Sivasubramanian N, Mann DL. The role of cytokines in the failing human heart. Cardiol Clin. 1998;16:645-656, viii.
8. Mann DL. Stress activated cytokines and the heart. Cytokine Growth Factor Rev. 1996;7:341-354.
9. Kubota T, McTiernan CF, Frye CS, Demetris AJ, Feldman AM. Cardiac-specific overexpression of tumor necrosis factor-α causes lethal myocarditis in transgenic mice. J Card Fail. 1997;3:117-124.
10. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81:627-035.
11. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation. 1998;97:1375-1381.
12. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, Mann DL. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104:826-831.
13. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 1995;92:4862-4866.
14. Ueshima K, Shibata M, Suzuki T, Endo S, Hiramori K. Extracellular matrix disturbances in acute myocardial infarction: relation between disease severity and matrix metalloproteinase-1, and effects of magnesium pretreatment on reperfusion injury. Magnes Res. 2003;16:120-126.
15. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-1725.
16. Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen WH, Shou Z, Liu P. Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation. 1999;99:1492-1498.
17. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000;12:1-13.
18. Muegge K, Durum SK. Cytokines and transcription factors. Cytokine. 1990;2:1-8.
19. Spriggs DR, Deutsch S, Kufe DW. Genomic structure, induction, and production of TNF-α. Immunol Ser. 1992;56:3-34.
20. Szatmary Z. Tumor necrosis factor-α: molecular-biological aspects minireview. Neoplasma. 1999;46:257-266.
21. Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor α mRNA stability. Mol Cell Biol. 2001;21:6461-6469.
22. Chung YJ, Zhou HR, Pestka JJ. Transcriptional and posttranscriptional roles for p38 mitogen-activated protein kinase in upregulation of TNF-α expression by deoxynivalenol (vomitoxin). Toxicol Appl Pharmacol. 2003;193:188-201.
23. Craig R, Larkin A, Mingo AM, Thuerauf DJ, Andrews C, McDonough PM, Glembotski CC. p38 MAPK and NF-κB collaborate to induce interleukin-6 gene expression and release: evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem. 2000;275:23814-23824.
24. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998;274:R577-R595.
25. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury: relationship to ischemic preconditioning. Basic Res Cardiol. 2002;97:276-285.
26. Petrich BG, Wang Y. Stress-activated MAP kinases in heart failure: new insights from in vivo studies. Trends Cardiovasc Med. 2004;14:50-55.
27. Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H, Saffitz J, Chien K, Xiao RP, Kass DA, Wang Y. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A. 2001;98:12283-12288.
28. Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, Ohlstein EH, Angermann CE, Adams JL, Sisko J, Sackner-Bernstein JD, Willette RN. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation. 2001;104:1292-1298.
29. Kohout TA, O'Brian JJ, Gaa ST, Lederer WJ, Rogers TB. Novel adenovirus component system that transferts cultured cardiac cells with high efficiency. Circ Res. 1996;78:971-977.
30. Overbergh L, Valckx D, Waer M, Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine. 1999;11:305-312.
31. Brower GL, Janicki JS. Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol. 2001;280:H674-H683.
32. Ohta S, Harigai M, Tanaka M, Kawaguchi Y, Sugiura T, Takagi K, Fukasawa C, Hara M, Kamatani N. Tumor necrosis factor-α (TNF-α) converting enzyme contributes to production of TNF-α in synovial tissues from patients with rheumatoid arthritis. J Rheumatol. 2001;28:1756-1763.
33. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273:2161-2168.
34. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
35. Oral H, Kapadia S, Nakano M, Torre-Amione G, Lee J, Lee-Jackson D, Young JB, Mann DL. Tumor necrosis factor-α and the failing human heart. Clin Cardiol. 1995;18:IV20-IV27.
36. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 1995;96:1042-1052.
37. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
38. Kubota T, Miyagishima M, Alvarez RJ, Kormos R, Rosenblum WD, Demetris AJ, Semigran MJ, Dec GW, Holubkov R, McTiernan CF, Mann DL, Feldman AM, McNamara DM. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant. 2000;19:819-824.
39. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-1493.
40. Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-α gene and protein expression in adult feline myocardium. Circ Res. 1997;81:187-195.
41. Torre-Amione G, MacLellan W, Kapadia S, Weilbaecher D, Farmer J, Young J, Mann D. Tumor necrosis factor-α is persistently expressed in cardiac allografts in the absence of histological or clinical evidence of rejection. Transplant Proc. 1998;30:875-877.
42. Baumgarten G, Knuefermann P, Nozaki N, Sivasubramanian N, Mann DL, Vallejo JG. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J Infect Dis. 2001;183:1617-1624.
43. Nakano M, Knowlton AA, Yokoyama T, Lesslauer W, Mann DL. Tumor necrosis factor-α-induced expression of heat shock protein 72 in adult feline cardiac myocytes. Am J Physiol. 1996;270:H1231-H1239.
44. Nakano M, Knowlton AA, Dibbs Z, Mann DL. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation. 1998;97:1392-1400.
45. Wada H, Saito K, Kanda T, Kobayashi I, Fujii H, Fujigaki S, Maekawa N, Takatsu H, Fujiwara H, Sekikawa K, Seishima M. Tumor necrosis factor-α (TNF-α) plays a protective role in acute viral myocarditis in mice: a study using mice lacking TNF-α. Circulation. 2001;103:743-749.
46. Oral H, Dorn GW 2nd, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J Biol Chem. 1997;272:4836-4832.
47. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95;1247-1252.
48. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382-1391.
49. Liao P, Wang SQ, Wang S, Zheng M, Zhang SJ, Cheng H, Wang Y, Xiao RP. p38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res. 2002;90:190-196.
50. Wollen KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95-103.
51. Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta. 2002;1592:323-343.
52. Yamauchi-Takihara K. Gp130-mediated pathway and left ventricular remodeling. J Card Fail. 2002;8:S374-S378.
53. Wang Y. Signal transduction in cardiac hypertrophy: dissecting compensatory versus pathological pathways utilizing a transgenic approach. Curr Opin Pharmacol. 2001;1:134-140.
54. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta. 1996;1317:84-94.
55. Filipeanu CM, Zhou F, Claycomb WC, Wu G. Regulation of the cell surface expression and function of angiotensin II type 1 receptor by Rab1-mediated endoplasmic reticulum-to-Golgi transport in cardiac myocytes. J Biol Chem. 2004;279:41077-41084.
56. Fischer TA, Ungureanu-Longrois D, Singh K, de Zengotita J, DeUgarte D, Alali A, Gadbut AP, Lee MA, Balligand JL, Kifor I, Smith TW, Kelly RA. Regulation of bFGF expression and ANG II secretion in cardiac myocytes and microvascular endothelial cells. Am J Physiol. 1997;272:H958-H968.
57. De Young MB, Keller JC, Graham RM, Wildey GM. Brefeldin A defines distinct pathways for atrial natriuretic factor secretion in neonatal rat atrial and ventricular myocytes. Circ Res. 1994;74:33-40.
58. Diaz-Rodriguez E, Montera JC, Esparis-Ogando A, Yuste L, Pandiella A. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor α-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell. 2002;13:2031-2044.
59. Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N, Wilson EM, Spinale FG, Mann DL. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2003;109:262-268.
60. Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, Wang C, Lee JC, Feuerstein GZ, Yue TL. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 1999;99:1685-1691.
61. Fijen JW, Zijlstra JG, De Boer P, Spanjersberg R, Tervaert JW, Van Der Werf TS, Ligtenberg JJ, Tulleken JE. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol. 2001;124:16-20.
62. Krum H, Fijen JW, Zijlstra JG, De Boer P, Spanjersberg R, Tervaert JW, Van Der Werf TS, Ligtenberg JJ, Tulleken JE, Bolger AP, Anker SD, Meldrum DR, Donnahoo KK. New and emerging pharmacological strategies in the management of chronic heart failure. Curr Opin Pharmacol. 2001;1:126-133.